The effects of increasing levels of quinolone resistance on in-vitro activity of four quinolones

Journal of Antimicrobial Chemotherapy

Volumn 42, Issue 2, 1998, Pages 179-187

  Thomson, Kenneth S ^a   Sanders, Christine C ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; NALIDIXIC ACID; OFLOXACIN; SITAFLOXACIN; TEMAFLOXACIN;

ANTIBIOTIC RESISTANCE; ARTICLE; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STAPHYLOCOCCUS;

EID: 0031825328     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/42.2.179     Document Type: Article

References (14)

1. Thomson, K. S., Sanders, C. C. & Hayden, M. E. (1991). In vitro studies with five quinolones: evidence for changes in relative potency as quinolone resistance rises. Antimicrobial Agents and Chemotherapy 35, 2329-34.
2. Sanders, C. C. (1990). Microbiology of fluoroquinolones. In Fluoroquinolones in the Treatment of Infectious Diseases (Sanders, J., Eugene, W. & Sanders, C. C., Eds), pp. 1-28. Physicians and Scientists Publishing Co., Glenview.
3. Oram, M. & Fisher, L. M. (1991). 4-Quinolone resistance mutations in the DNA gyrase of Escherichia coli clinical isolates identified by using the polymerase chain reaction. Antimicrobial Agents and Chemotherapy 35, 387-9.
4. Hooper, D. C. & Wolfson, J. S. (1993). Mechanism of bacterial resistance to quinolones. In Quinolone Antimicrobial Agents, 2nd edn (Hooper, D. C. & Wolfson, J. S., Eds), pp. 97-118. American Society for Microbiology, Washington, DC.
5. Doss, S. A., Tillotson, G. S., Barg, N. L. & Amyes, S. G. B. (1995). In-vitro and in-vivo selection of Staphylococcus aureus mutants resistant to ciprofloxacin. Journal of Antimicrobial Chemotherapy 35, 95-102.
6. Sanders, C. C., Sanders, W. E. & Thomson, K. S. (1995). Fluoroquinolone resistance in staphylococci: new challenges. European Journal of Clinical Microbiology and Infectious Diseases 14, Suppl. 1, 6-11.
7. National Committee for Clinical Laboratory Standards. (1997). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically. Approved Standard M7-A4. National Committee for Clinical Laboratory Standards, Villanova, PA.
8. Pena, C., Albareda, J. M., Pollares, R., Pujol, M. M., Tubau, F. & Ariza, J. (1995). Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections. Antimicrobial Agents and Chemotherapy 39, 520-4.
9. Thomson, K. S., Sanders, W. E. & Sanders, C. C. (1994). USA resistance patterns among UTI pathogens. Journal of Antimicrobial Chemotherapy 33, Suppl. A, 9-15.
10. Everett, M. J., Jin, Y. F., Ricci, V. & Piddock, L. J. V. (1996). Contributions of individual mechanisms to fluoroquinolone resistance in 36 Escherichia coli strains isolated from humans and animals. Antimicrobial Agents and Chemotherapy 40, 2380-6.
11. Ng, E. Y., Trucksis, M. & Hooper, D. C. (1996). Quinolone resistant mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 40, 1881-8.
12. Nakane, T., Iyobe, S., Sato, K. & Mitsuhashi, S. (1995). In vitro activity of Du-6859a, a new fluoroquinolone. Antimicrobial Agents and Chemotherapy 39, 2822-6.
13. Marshall, S. A. & Jones, R. A. (1993). In vitro activity of Du-6859a, a new fluorocyclopropyl quinolone. Antimicrobial Agents and Chemotherapy 37, 2747-53.
14. Tanaka, M., Hoshimo, K., Hohmura, M., Ishida, H., Kitamura, A., Sato, K. et al. (1996). Effect of growth conditions on antimicrobial activity of Du-6859a and its bactericidal activity determined by the killing curve method. Journal of Antimicrobial Chemotherapy 37, 1091.